Navigation Links
Generex Provides Additional Details for October 21st Live Video Webcast
Date:10/20/2010

be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an early ... is very pleased to announce that the Musculoskeletal Transplant ... agreed to invest in their seed round of development ... tissue storage capabilities. AmnioChor,s technology allows ... the human stem cells living within those tissues. Amnion ...
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index ... , in particular, drug/device combinations. The current system received a score of 0 (range ... Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... Inc. ("Chromos" or the "Company"; TSX: CHR) today provided ... of Directors of Chromos today announced that Mr. Alistair,Duncan ... effective,immediately. He has also resigned as a Director of ... President and CEO since 1998., Mr. Roger Flowerdew, ...
... Education and Finger Health in Diabetes Management, ... 16 Pelikan,Technologies Inc., a leading developer ... Eli Lilly and Company today announced the,signing ... terms of the,co-promotion agreement, the companies will ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan,Melcher ... Hospital in Leeds,U.K. published the results of their ... Therapy. The paper is entitled "Inflammatory Tumour Cell ... The investigators showed that reovirus effectively kills ...
Cached Biology Technology:Chromos provides shareholder update 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 3Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 4Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma 2
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... here have used a new microscopic, three-dimensional scaffolding to coax ... then to function identical to how fat cells naturally do ... fat cells, or adipocytes, in the laboratory, those cells never ... tissue. They failed to produce the genetic and biologic components ...
... have discovered a potential new drug that inhibits destructive ... all cancers. The scientists showed they could block the ... compound, called cysmethynil. , Their finding, reported in the ... Academy of Sciences, is the first step toward developing ...
... To understand the formation of the brain-clogging deposits ... diseases, Duke University chemists have figured out how ... blocks of the deposits. , Their aim is ... toxic protein called amyloid plaque. Such basic understanding, ...
Cached Biology News:Tiny scaffolding allows stem cells to become working fat cells 2Tiny scaffolding allows stem cells to become working fat cells 3Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimer's, Parkinson's Disease 2
... HEEBO (Human Exonic Evidence Based Oligonucleotide) Genome ... Oligonucleotide ) Genome Set contain a collection ... from constitutively expressed exons, allowing interrogation of ... leading researchers at Stanford University and UCSF, ...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
...
Biology Products: